BDBM135815 US10085990, Example 51::US10568888, Example 51::US8853226, 51::US9393245, 51::US9833457, 51

SMILES COc1cccc2c1ncc1c2n(C2CCCC2)c(=O)n(-c2cc(C)cs2)c1=O

InChI Key InChIKey=XBMCCMKXNQMPDO-UHFFFAOYSA-N

Data  12 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 12 hits for monomerid = 135815   

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
High Point Pharmaceuticals

US Patent
LigandPNGBDBM135815(US8853226, 51 | US9393245, 51 | US10085990, Exampl...)
Affinity DataIC50: 126nMAssay Description:A TR-FRET-based phosphodiesterase assay kit from "Molecular Devices" was used to test whether these compounds were indeed direct inhibitors of the PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2015
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
High Point Pharmaceuticals

US Patent
LigandPNGBDBM135815(US8853226, 51 | US9393245, 51 | US10085990, Exampl...)
Affinity DataIC50: 616nMAssay Description:A TR-FRET-based phosphodiesterase assay kit from "Molecular Devices" was used to test whether these compounds were indeed direct inhibitors of the PD...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/16/2015
Entry Details
Go to US Patent

TargetTumor necrosis factor(Human)
Vtv Therapeutics

US Patent
LigandPNGBDBM135815(US8853226, 51 | US9393245, 51 | US10085990, Exampl...)
Affinity DataIC50: 30nMT: 2°CAssay Description:Add 100 μL of sample or standards in Reagent Diluent, or an appropriate diluent, per well. Cover with an adhesive strip and incubate 2 hours at ro...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2017
Entry Details
Go to US Patent

LigandPNGBDBM135815(US8853226, 51 | US9393245, 51 | US10085990, Exampl...)
Affinity DataIC50: 126nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2017
Entry Details
Go to US Patent

LigandPNGBDBM135815(US8853226, 51 | US9393245, 51 | US10085990, Exampl...)
Affinity DataIC50: 616nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffe...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/26/2017
Entry Details
Go to US Patent

LigandPNGBDBM135815(US8853226, 51 | US9393245, 51 | US10085990, Exampl...)
Affinity DataIC50: 30nMAssay Description:Samples were tested for TNF as per the manufacturer's instructions (TNF ELISA; R&D Systems, Cat #DY210). The samples were serially diluted with P...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
High Point Pharmaceuticals

US Patent
LigandPNGBDBM135815(US8853226, 51 | US9393245, 51 | US10085990, Exampl...)
Affinity DataIC50: 126nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
High Point Pharmaceuticals

US Patent
LigandPNGBDBM135815(US8853226, 51 | US9393245, 51 | US10085990, Exampl...)
Affinity DataIC50: 616nMT: 2°CAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/17/2019
Entry Details
Go to US Patent

LigandPNGBDBM135815(US8853226, 51 | US9393245, 51 | US10085990, Exampl...)
Affinity DataIC50: 126nMAssay Description:A TR-FRET-based phosphodiesterase assay kit from Molecular Devices was used to test whether these compounds were indeed direct inhibitors of the PDE4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
High Point Pharmaceuticals

US Patent
LigandPNGBDBM135815(US8853226, 51 | US9393245, 51 | US10085990, Exampl...)
Affinity DataIC50: 616nMAssay Description:A TR-FRET-based phosphodiesterase assay kit from Molecular Devices was used to test whether these compounds were indeed direct inhibitors of the PDE4...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/28/2019
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4B(Human)
High Point Pharmaceuticals

US Patent
LigandPNGBDBM135815(US8853226, 51 | US9393245, 51 | US10085990, Exampl...)
Affinity DataIC50: 126nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent

TargetcAMP-specific 3',5'-cyclic phosphodiesterase 4D(Human)
High Point Pharmaceuticals

US Patent
LigandPNGBDBM135815(US8853226, 51 | US9393245, 51 | US10085990, Exampl...)
Affinity DataIC50: 616nMAssay Description:The assay buffer was prepared by diluting 5× supplied Tween-based buffer in 1:5 in water to make 1× buffer. Add desired additive to buffer (DTT or Mn...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/30/2020
Entry Details
Go to US Patent